Pfenex Inc. is a development‐stage biopharmaceutical company leveraging its proprietary Pfenex® Expression Technology to produce biosimilar and novel therapeutic proteins. The platform employs a high‐yield bacterial expression host derived from Pseudomonas fluorescens, enabling cost‐efficient, scalable manufacturing of protein‐based drugs and active pharmaceutical ingredients for a range of clinical applications.
The company’s lead biosimilar candidate, PF708, is a proposed biosimilar to Neulasta® (pegfilgrastim) being advanced under a global collaboration with Pfizer. In parallel, Pfenex is developing PF745, an on‐body injector formulation of pegfilgrastim. Beyond oncology support tools, the pipeline encompasses recombinant vaccines and immunotherapies for respiratory and other infectious diseases, bolstered by the strategic acquisition of Dianthus Therapeutics in 2021, which added novel adjuvant and mRNA delivery technology.
Headquartered in San Diego, California, and founded in 2009, Pfenex serves pharmaceutical and biotech clients worldwide through its contract development and manufacturing (CDMO) services. The company supports partners through discovery, development, and scale‐up stages, addressing markets in North America, Europe and Asia with its high‐performance bacterial expression system.
Pfenex is guided by a management team with deep expertise in biologics development, regulatory affairs and commercial manufacturing. This leadership has steered the company through key clinical milestones, regulatory interactions and strategic partnerships, positioning Pfenex to deliver cost‐effective protein therapeutics and capitalize on opportunities in the expanding biosimilars and vaccine markets.
AI Generated. May Contain Errors.
